Alnylam Pharmaceuticals Stock Earnings Report NASDAQ:ALNY
Current P/E ratio: -22.97 | Price (June 22, 2021, EOD): $172.95 (Find current average P/E ratios for all sectors below)
ALNY Upcoming EarningsCurrently no data available.
ALNY Analysts Price TargetsCurrently no data available.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference. The companys clinical development programs include Patisiran and Revusiran, which are in Phase III clinical trials for the treatment of transthyretin amyloidosis (ATTR); ALN-TTRsc02, an investigational RNAi therapeutic targeting TTR for the treatment of various forms of ATTR amyloidosis; Fitusiran, an investigational RNAi therapeutic that is in Phase I clinical trial for the treatment of hemophilia and rare bleeding disorders; ALN-CC5, which is in Phase I/II clinical trial for the treatment of complement-mediated diseases; and ALN-AS1 for the treatment of hepatic porphyrias. Its product development programs also include ALN-AAT for the treatment of alpha-1 antitrypsin deficiency-associated liver disease; ALN-PCSsc that is in Phase I clinical trial for hypercholesterolemia; ALN-HBV for the treatment of Hepatitis B virus; ALN-AC3 for the treatment of hypertriglyceridemia; ANGPTL3 for the treatment of hypertriglyceridemia and mixed hyperlipidemia; ALN-AGT for the treatment of hypertensive disorders of pregnancy, including preeclampsia; ALN-GO1 for the treatment of primary hyperoxaluria type 1; ALN-HDV for the treatment of HDV infection; and ALN-PDL for the treatment of chronic liver infections. The company has strategic alliances and collaboration agreements with Ionis Pharmaceuticals, Inc.; Novartis Pharma AG; Novartis/Arrowhead; F. Hoffmann-La Roche Ltd; Roche/Arrowhead; Takeda Pharmaceutical Company Limited; Kyowa Hakko Kirin Co., Ltd.; Cubist Pharmaceuticals, Inc.; Ascletis BioScience Co., Ltd.; Monsanto Company; Sanofi Genzyme; The Medicines Company; Arbutus Biopharma Corporation; Protiva Biotherapeutics, Inc.; The University of British Columbia; and Acuitas Therapeutics Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Last 3 Quarters for ALNY Premium
Below you can see how ALNY performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.
Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.
What To Know About Earnings Reports
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
Average Sector P/E ratio
Is your stock priced above or below the average P/E ratio?
A higher P/E ratio shows that investors are willing to pay a higher share price today because of growth expectations in the future. For example, a company with a current P/E of 25, trades at 25 times today's earnings.
|Name||Number of firms||Average PE|
|Auto & Truck||13||15|
|Bank (Money Center)||7||11|
|Brokerage & Investment Banking||39||14|
|Business & Consumer Services||165||32|
|Coal & Related Energy||22||7|
|Electronics (Consumer & Office)||20||18|
|Environmental & Waste Services||82||70|
|Financial Svcs. (Non-bank & Insurance)||232||36|
|Green & Renewable Energy||22||88|
|Healthcare Support Services||128||131|
|Heathcare Information and Technology||129||132|
|Investments & Asset Management||192||120|
|Metals & Mining||92||37|
|Office Equipment & Services||22||16|
|Oil/Gas (Production and Exploration)||269||19|
|Packaging & Container||24||43|
|Publishing & Newspapers||31||28|
|Real Estate (Development)||20||146|
|Real Estate (General/Diversified)||12||31|
|Real Estate (Operations & Services)||57||23|
|Retail (Building Supply)||17||202|
|Retail (Grocery and Food)||13||38|
|Retail (Special Lines)||89||25|
|Shipbuilding & Marine||10||30|
|Software (System & Application)||363||144|
|Total Market (without financials)||5878||62|
Updated: Jan 2020
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.